Investors

Investor Relations

Akebia Therapeutics

Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization.

We have a portfolio focused on addressing significant unmet needs for people living with kidney disease.

OUR MEDICINE

RESEARCH & DEVELOPMENT

Press Releases

April 2, 2024

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 27, 2024

Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis

March 14, 2024

Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

VIEW ALL PRESS RELEASES

Events & Presentations

March 28, 2024 at 8:00 AM EDT

Akebia Conference Call to Discuss FDA Approval

January 11, 2024 at 11:15 AM PST

42nd Annual J.P. Morgan Healthcare Conference

November 28, 2023 at 10:30 AM EST

2023 Piper Sandler Healthcare Conference

VIEW ALL EVENTS

Data Presentations

Presented at ASN Kidney Week 2021

Comprehensive Safety Profile of Vadadustat from Global Phase 3 Clinical Trials

Presented at ASN Kidney Week 2021

Vadadustat for Treatment of Anemia in Patients with Dialysis-Dependent CKD Receiving Peritoneal Dialysis

Presented at ASN Kidney Week 2021

Vadadustat, an Oral HIF-PHI, Is Not Associated with Increased Risk of Neoplasm in Patients with Anemia Due to CKD

VIEW ALL DATA PRESENTATIONS

Volume:

Today’s Open:

Previous Close:

Print Page

Email Page

Contact IR

Email Alerts

Tear Sheet

Akebia Therapeutics, Inc.
245 First Street, Suite 1400
Cambridge, MA 02142

Driving Directions

+1 617.871.2098 phone
+1 617.871.2099 fax